Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1994-7-15
|
pubmed:abstractText |
Echinomycin is a novel bifunctional intercalating agent derived from Streptomyces echinatus. A phase II clinical trial of echinomycin in patients with advanced, measurable colorectal cancer was initiated to determine the efficacy and toxicities of this agent. Echinomycin, 1.5 mg/m2, was given initially as a 30- to 60-min infusion every 4 weeks. After 4 episodes of anaphylaxis had occurred among the first 14 patients, the schedule was changed to a 24-h infusion, and an additional 16 patients were treated on this schedule. Treatment was given every 3 weeks. A total of 30 patients were eligible and evaluable; there were 3 (10%; 90% confidence interval, 3%-23%) clinical responses lasting 3, 3+, and 12 months, respectively. The most serious toxicity encountered was anaphylaxis, which occurred in 5 patients, although with no serious sequelae. A premedication regimen with dexamethasone, diphenhydramine, and cimetidine and a change of the duration of the infusion to 24 h reduced the incidence of this complication. Grade 2-3 vomiting occurred among earlier patients treated; however, with the 24-h schedule this toxicity was substantially reduced. The sole important case of hematologic toxicity was a single patient with grade 3 thrombocytopenia. Echinomycin employed in this dose and schedule had modest activity against colorectal cancer, comparable with that observed with 5-fluorouracil. Further studies in patients with gastrointestinal malignancies using a 24-h infusion with a dexamethasone premedication regimen similar to that employed prior to administration of taxol may be warranted.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0344-5704
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
266-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8004762-Adenocarcinoma,
pubmed-meshheading:8004762-Adult,
pubmed-meshheading:8004762-Aged,
pubmed-meshheading:8004762-Aged, 80 and over,
pubmed-meshheading:8004762-Colorectal Neoplasms,
pubmed-meshheading:8004762-Echinomycin,
pubmed-meshheading:8004762-Female,
pubmed-meshheading:8004762-Humans,
pubmed-meshheading:8004762-Male,
pubmed-meshheading:8004762-Middle Aged,
pubmed-meshheading:8004762-Neoplasm Recurrence, Local,
pubmed-meshheading:8004762-Survival Analysis,
pubmed-meshheading:8004762-Treatment Outcome
|
pubmed:year |
1994
|
pubmed:articleTitle |
Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer.
|
pubmed:affiliation |
Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10467.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|